Physicochemical Tuning of Nanoparticles for Enhanced Ocular Uptake

Study Background and Research Question

Ocular drug delivery poses persistent challenges due to anatomical and physiological barriers that limit drug penetration and retention at the eye surface. Despite the prevalence of topical formulations, their clinical utility is often hampered by rapid clearance via tear fluid, poor permeability across the corneal epithelium, and low overall bioavailability. Traditional strategies such as viscosity and penetration enhancers, ointments, and prodrugs can improve some pharmacokinetic properties but frequently cause discomfort, irritation, or blurred vision. As a result, there is significant interest in leveraging nanoparticle-based drug carriers that offer enhanced retention, controlled release, and improved tissue penetration. However, the precise mechanisms by which nanoparticle physicochemical characteristics—such as size and surface chemistry—influence cellular uptake by corneal tissues remain incompletely understood.

Key Innovation from the Reference Study

The reference study by Azadi and David (ACS Biomater. Sci. Eng. 2024, 10, 429−441) systematically investigates how the size and surface properties of poly(lactic-co-glycolic) acid (PLGA) nanoparticles affect their interactions with and uptake by human cornea epithelial cells (HCECs). By employing a panel of nanoparticles with controlled dimensions (100–250 nm) and tailored surface modifications—mucoadhesive coatings (alginate, chitosan) and mucopenetrative PEGylation—the study uncovers the dominant cellular entry routes and identifies design parameters that optimize cellular uptake for potential ocular drug delivery applications.

Methods and Experimental Design Insights

PLGA nanoparticles were synthesized using the emulsion-solvent evaporation method. Surface modification was achieved by coating with either mucoadhesive polymers (alginate, chitosan) or mucopenetrative polyethylene glycol (PEG). The resulting particles were highly uniform (polydispersity index below 0.2), spherical, and displayed zeta potentials ranging from −25 mV to +15 mV depending on the surface coating. Particle sizes were precisely controlled between 100 and 250 nm.

To mimic the ocular surface, an in vitro model comprising a monolayer of HCECs integrated with simulated mucosal solution was developed. Cytotoxicity was evaluated using the MTT assay, confirming that nanoparticle exposure up to 100 μg/mL for 24 hours resulted in only mild toxicity (cell viability 70–100%). Cellular uptake was quantified under various conditions, including in the presence of selective endocytosis inhibitors to dissect the contributions of specific internalization pathways: macropinocytosis, caveolae-mediated, and clathrin-mediated endocytosis.

Core Findings and Why They Matter

The study delivers several important findings with direct translational relevance:

• Optimal Size for Uptake: Nanoparticles at the lower end of the tested size range (100 nm) exhibited the highest uptake by HCECs, aligning with the hypothesis that smaller particles more readily navigate the dense corneal epithelial barrier.
• Surface Chemistry Effects: PEGylated PLGA nanoparticles (PEG-PLGA-150) showed superior uptake compared to unmodified or mucoadhesive-coated variants, suggesting that mucopenetrative properties facilitate traversal of the mucous layer and subsequent cellular entry.
• Endocytic Pathway Specificity: Using pharmacological inhibitors, the authors establish that nanoparticle uptake is predominantly energy-dependent, with macropinocytosis and caveolae-mediated endocytosis as the principal internalization routes. Clathrin-mediated uptake contributes to a lesser extent, while phagocytosis is not involved under the tested conditions.
• Low Cytotoxicity: The nanoparticle formulations tested maintained high cell viability, supporting their suitability for ocular application.

These results provide a rational framework for designing nanoparticle-based ocular therapeutics: prioritizing sub-150 nm, PEGylated formulations to maximize corneal epithelial uptake while minimizing irritation or off-target effects. Furthermore, delineating the dominant endocytic pathways offers a foundation for future studies aiming to fine-tune drug delivery or to co-administer pathway-specific modulators.

Comparison with Existing Internal Articles

While the reference study centers on nanoparticle-cell interactions in the ocular epithelium, parallels exist with inhibitor-based mechanistic research in other systems. For example, Wei et al. (Spiroplasma eriocheiris Entry Mechanisms in Drosophila S2 Cells) used pharmacological inhibitors to distinguish between clathrin- and caveolae-mediated endocytosis in a host-pathogen context. Their work, although in invertebrate cells, reinforces the utility of chemical inhibition to dissect endocytic pathways—an approach mirrored in the nanoparticle uptake study. Additionally, resources such as Rottlerin (B6803): Selective PKCδ Inhibitor detail the use of small-molecule inhibitors to probe cell signaling and proliferation, which can complement nanoparticle research by clarifying downstream functional consequences of uptake (e.g., cell proliferation inhibition, apoptosis induction).

Limitations and Transferability

Despite its strengths, the study's principal limitation lies in its reliance on an in vitro model system. While the HCEC monolayer with simulated mucosal solution approximates key features of the ocular surface, it does not fully capture the complexity of in vivo tear turnover, immune surveillance, or multi-layer tissue architecture. The uptake pathways identified may be altered in the presence of dynamic tear flow or in diseased states. Likewise, the absence of phagocytosis observed may not extrapolate to other cell types present in the cornea or conjunctiva in vivo. Caution is warranted in directly translating these findings to clinical formulations; further studies in animal models are needed to validate bioavailability and safety under physiological conditions.

Protocol Parameters

• Nanoparticle synthesis: Use emulsion-solvent evaporation for PLGA NPs; tune parameters to control size (100–250 nm).
• Surface functionalization: Modify with PEG for mucopenetration or with alginate/chitosan for mucoadhesion.
• Cytotoxicity testing: MTT assay at 24 h exposure up to 100 μg/mL to ensure ≥70% cell viability.
• Uptake studies: Incubate nanoparticles with HCECs in simulated mucosal solution; apply energy-dependence and pathway-specific inhibitors as appropriate.

Research Support Resources

For researchers exploring nanoparticle-cell interactions, especially those involving endocytosis and downstream signaling such as cell proliferation inhibition or apoptosis induction, selective pathway inhibitors are essential tools. Rottlerin (SKU B6803) is a well-characterized PKC inhibitor, notably selective for PKCδ, and has been used to interrogate signaling events including caspase-3 activation and PARP cleavage in various cell systems. When designing experiments to dissect the effects of nanoparticle uptake on cellular behavior, Rottlerin can be incorporated as a mechanistic probe to clarify the role of PKC-dependent pathways. For detailed protocols and troubleshooting, APExBIO provides validated resources and technical support to facilitate rigorous, reproducible research workflows.